Inversago Pharma Inc., of Montreal, said it closed a $7 million series A financing to support the development of new generations of cannabinoid-1 (CB1) receptor blockers. The round was co-led by Genesys Capital and Amorchem, with participation from the JDRF T1D Fund, Accel-Rx, Anges Québec Capital, Anges Québec, Tarnagulla Ventures and angel investors.